Diagnosis was made clinically, followed by CT as soon as possible. In all our patients, initial CT showed no relevant abnormality.
Recanalisation was assessed by angiography in two cases and by TCD in 14 cases. In two patients, no assessment of recanalisation was performed because they survived less than 24 hours.
Recanalisation was considered to have occurred if angiography or TCD showed a patent basilar artery; recanalisation was regarded as not achieved if the vessel remained occluded, or if a high grade stenosis was found with relevant haemodynamic consequences.
The time from onset of symptoms to the start of the thrombolytic treatment was less than six hours in 13 patients, seven hours in one patient, and in one patient the period could not be assessed precisely from the case record.
Heparin was given to every patient after the thrombolytic procedure in a dosage (usually 800 to 1000 IU/h) suitable to maintain the activated partial thromboplastin time at 1-5 to twice normal. In addition, conventional stroke treatment with hydroxyethyl starch (500 ml for five days) and intravenous pentoxifylline (200 mg/day) was given routinely.
Computed tomography was performed after the thrombolytic treatment in every case, and repeated at intervals both routinely and with respect to clinical changes.
Clinical outcome was primarily assessed as survival and death. In the case of survival, outcome was regarded as not favourable if there was total dependence on nursing care, and as favourable, if independence from constant support was achieved.
Results
Sixteen patients aged between 31 and 78 had systemic thrombolytic treatment. Five patients survived, three with a favourable outcome. Eleven patients died. The patients who survived were younger than 51, with the exception of a 74 year old man, who recovered well. In all survivors, recanalisation was accomplished. All 11 patients who died were older than 50. In six of them, recanalisation was achieved (table) . Recanalisation was achieved in 10 patients (62%), five of whom survived. All six patients in whom recanalisation could not be achieved died (table). In the subgroup older than 50, recanalisation was achieved in seven out of 13 cases (54%).
Three of the five patients who died after recanalisation had severe non-cerebral complications that led to death after appreciable recovery from their initial neurological deficits. A 59 year old woman died on day three from acute myocardial infarction. A 53 year old man died of acute cardiac failure on day eight; cor bovinum and hepatic cirrhosis were present at necropsy. A 66 year old man died 33 days after thrombolytic treatment as a result of urosepsis based on a pre-existing chronic pyelonephritis.
Twelve patients were comatose on admission. In six of these patients recanalisation was achieved. Only two of the six recanalised patients survived.
Recanalisation was accomplished in the four patients who were not comatose on admission and three of them survived.
Bleeding complications occurred, with major intracerebral haemorrhages in two patients (12-5%). In a 43 year old man, a haemorrhage was found in the frontoparietal region of the right hemisphere by routine CT. The haemorrhage did not affect a good clinical outcome. A pontine haemorrhage occurred in a 78 year old woman, who died on day 16 after thrombolysis in an unresolved comatose state. Brain necropsy showed pronounced atherosclerotic changes in the basal brain vessels.
Discussion
Despite the few patients and sparse reports in the literature it is considered that lysis induced recanalisation of the basilar artery can be of benefit to the patient. Systemic thrombolysis-first described in an encouraging case report by Wildemann et al,4 and subsequently by von Kummer et al5 with a poor outcome in four of five patients-has not been widely used as a therapeutic approach.
In our series of 16 patients, the outcome seems to be dependent on recanalisation of the occluded vessel, as previously reported.
Recanalisation is mandatory for survival, although it does not guarantee it; nonrecanalisation is inevitably correlated with bad clinical outcome (100% died).
Our experience indicates that survival of a patient older than 50 is a rare event, even if recanalisation is achieved. Nevertheless, in seven of 13 (54%) patients older than 50 recanalisation was achieved.
It is important to note that of the five patients who died despite recanalisation, three had severe non-cerebral complications. If these non-cerebral causes of death are excluded, the success rate improves with eight survivors v two cerebral causes of death in those patients with recanalisation. Thus our data suggest that poor clinical outcome, especially in elderly patients, is more often due to concomitant medical illness (three of five (60%)).
Moreover, in patients with initial coma, recanalisation is less likely to be achieved (only 50% in our series) and survival is less probable even with recanalisation.
A In conclusion, we believe that systemic thrombolytic treatment is a valuable tool for treating acute occlusion of the basilar artery. The results seem comparable with those achieved by a topical thrombolysis. Although outcome in patients younger than 50 seems most promising, its application should not be withheld from older patients, for benefit may result, especially in the absence of initial coma and concomitant medical illness. 
